Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules April 14, 2022 • 4:05 PM EDT
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules April 12, 2022 • 8:30 AM EDT
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting April 11, 2022 • 2:30 PM EDT
Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference March 22, 2022 • 8:00 AM EDT
Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting March 15, 2022 • 7:00 AM EDT
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update February 11, 2022 • 8:15 AM EST
Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022 February 4, 2022 • 7:00 AM EST
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells February 3, 2022 • 7:00 AM EST
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma January 12, 2022 • 8:00 AM EST